AtriCure, Inc. – NASDAQ:ATRC

AtriCure stock price today

$35.5
+4.85
+15.82%
Financial Health
0
1
2
3
4
5
6
7
8
9

AtriCure stock price monthly change

+32.17%
month

AtriCure stock price quarterly change

+32.17%
quarter

AtriCure stock price yearly change

-17.39%
year

AtriCure key metrics

Market Cap
1.49B
Enterprise value
1.92B
P/E
-41.34
EV/Sales
5.83
EV/EBITDA
-65.34
Price/Sales
5.80
Price/Book
4.19
PEG ratio
0.21
EPS
-0.79
Revenue
414.60M
EBITDA
-23.18M
Income
-37.23M
Revenue Q/Q
16.42%
Revenue Y/Y
18.69%
Profit margin
-14.06%
Oper. margin
-12.92%
Gross margin
74.44%
EBIT margin
-12.92%
EBITDA margin
-5.59%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

AtriCure stock price history

AtriCure stock forecast

AtriCure financial statements

AtriCure, Inc. (NASDAQ:ATRC): Profit margin
Jun 2023 100.91M -5.11M -5.07%
Sep 2023 98.29M -9.05M -9.21%
Dec 2023 106.54M -9.78M -9.19%
Mar 2024 108.85M -13.26M -12.19%
AtriCure, Inc. (NASDAQ:ATRC): Analyst Estimates
Sep 2025 130.20M -6.89M -5.3%
Oct 2025 129.55M -6.89M -5.32%
Dec 2025 140.19M -4.88M -3.48%
Mar 2026 136.03M -9.06M -6.66%
  • Analysts Price target

  • Financials & Ratios estimates

AtriCure, Inc. (NASDAQ:ATRC): Debt to assets
Jun 2023 594171000 131.74M 22.17%
Sep 2023 600271000 137.43M 22.9%
Dec 2023 613932000 147.76M 24.07%
Mar 2024 591628000 135.31M 22.87%
AtriCure, Inc. (NASDAQ:ATRC): Cash Flow
Jun 2023 3.01M -16.08M 2.99M
Sep 2023 1.52M 11.87M 132K
Dec 2023 4.03M -2.78M 2.35M
Mar 2024 -21.87M 9.64M -7.00M

AtriCure alternative data

AtriCure, Inc. (NASDAQ:ATRC): Employee count
Aug 2023 1,050
Sep 2023 1,050
Oct 2023 1,050
Nov 2023 1,050
Dec 2023 1,050
Jan 2024 1,050
Feb 2024 1,050
Mar 2024 1,200
Apr 2024 1,200
May 2024 1,200
Jun 2024 1,200
Jul 2024 1,200

AtriCure other data

78.51% -18.49%
of ATRC is owned by hedge funds
35.87M -8.29M
shares is hold by hedge funds

AtriCure, Inc. (NASDAQ:ATRC): Insider trades (number of shares)
Period Buy Sel
Nov 2023 0 1248
Mar 2024 0 11616
Apr 2024 0 1500
May 2024 5000 1500
Aug 2024 0 3500
Transaction Date Insider Security Shares Price per share Total value Source
Sale
YUEN MAGGIE director Common Stock 3,500 $24.07 $84,245
Purchase
PRIVITERA SALVATORE officer: Chief Te.. Common Stock 5,000 $22.25 $111,250
Sale
NOZNESKY JUSTIN J officer: Chief Mk.. Common Stock 1,500 $24.09 $36,135
Sale
NOZNESKY JUSTIN J officer: Chief Mk.. Common Stock 1,500 $30.39 $45,585
Sale
DAHLQUIST KARL S. officer: Chief Legal Officer
Common Stock 1,885 $32.16 $60,622
Sale
NOZNESKY JUSTIN J officer: Chief Mk.. Common Stock 1,500 $36.72 $55,080
Sale
DAHLQUIST KARL S. officer: Chief Legal Officer
Common Stock 8,231 $37.36 $307,510
Option
WIRICK ANGELA L officer: Chief Financial Officer
Common Stock 5,000 $16.95 $84,750
Option
WIRICK ANGELA L officer: Chief Financial Officer
Non-qualified Stock Option (right to buy) 5,000 $16.95 $84,750
Option
WHITE ROBERT S. director
Common Stock 10,000 $15.96 $159,600
Patent
Grant
Filling date: 25 Sep 2019 Issue date: 13 Sep 2022
Grant
Filling date: 14 Nov 2018 Issue date: 13 Sep 2022
Grant
Filling date: 16 Nov 2020 Issue date: 9 Aug 2022
Grant
Filling date: 4 Apr 2019 Issue date: 19 Jul 2022
Grant
Filling date: 11 Jan 2018 Issue date: 19 Jul 2022
Application
Filling date: 10 Dec 2021 Issue date: 30 Jun 2022
Application
Filling date: 17 Sep 2021 Issue date: 23 Jun 2022
Grant
Filling date: 8 Jul 2019 Issue date: 21 Jun 2022
Application
Filling date: 17 Feb 2022 Issue date: 2 Jun 2022
Application
Filling date: 8 Dec 2021 Issue date: 19 May 2022
Monday, 23 December 2024
businesswire.com
Tuesday, 29 October 2024
seekingalpha.com
zacks.com
zacks.com
businesswire.com
Wednesday, 16 October 2024
zacks.com
Tuesday, 15 October 2024
businesswire.com
Friday, 11 October 2024
zacks.com
Tuesday, 8 October 2024
businesswire.com
Thursday, 5 September 2024
time.com
Wednesday, 28 August 2024
zacks.com
Tuesday, 27 August 2024
businesswire.com
Friday, 23 August 2024
zacks.com
Wednesday, 31 July 2024
seekingalpha.com
Tuesday, 30 July 2024
zacks.com
zacks.com
Monday, 29 July 2024
businesswire.com
Wednesday, 24 July 2024
zacks.com
Friday, 28 June 2024
investorplace.com
Wednesday, 15 May 2024
businesswire.com
Thursday, 2 May 2024
Seeking Alpha
Wednesday, 1 May 2024
Zacks Investment Research
Zacks Investment Research
Friday, 19 April 2024
Zacks Investment Research
Thursday, 15 February 2024
Seeking Alpha
Zacks Investment Research
Zacks Investment Research
Friday, 10 November 2023
Seeking Alpha
Monday, 6 November 2023
Zacks Investment Research
Wednesday, 1 November 2023
Seeking Alpha
  • What's the price of AtriCure stock today?

    One share of AtriCure stock can currently be purchased for approximately $35.5.

  • When is AtriCure's next earnings date?

    Unfortunately, AtriCure's (ATRC) next earnings date is currently unknown.

  • Does AtriCure pay dividends?

    No, AtriCure does not pay dividends.

  • How much money does AtriCure make?

    AtriCure has a market capitalization of 1.49B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.84% to 399.25M US dollars.

  • What is AtriCure's stock symbol?

    AtriCure, Inc. is traded on the NASDAQ under the ticker symbol "ATRC".

  • What is AtriCure's primary industry?

    Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.

  • How do i buy shares of AtriCure?

    Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are AtriCure's key executives?

    AtriCure's management team includes the following people:

    • Mr. Michael H. Carrel Chief Executive Officer, Pres & Director(age: 54, pay: $1,100,000)
    • Mr. Douglas J. Seith Chief Operating Officer(age: 59, pay: $693,240)
    • Mr. Salvatore Privitera J.D. Chief Technical Officer(age: 58, pay: $471,150)
    • Mr. Justin J. Noznesky Chief Marketing & Strategy Officer(age: 47, pay: $470,380)
    • Ms. Angela L. Wirick CPA Chief Financial Officer(age: 47, pay: $402,240)
  • How many employees does AtriCure have?

    As Jul 2024, AtriCure employs 1,200 workers.

  • When AtriCure went public?

    AtriCure, Inc. is publicly traded company for more then 20 years since IPO on 5 Aug 2005.

  • What is AtriCure's official website?

    The official website for AtriCure is atricure.com.

  • Where are AtriCure's headquarters?

    AtriCure is headquartered at 7555 Innovation Way, Mason, OH.

  • How can i contact AtriCure?

    AtriCure's mailing address is 7555 Innovation Way, Mason, OH and company can be reached via phone at +51 37554100.

AtriCure company profile:

AtriCure, Inc.

atricure.com
Exchange:

NASDAQ

Full time employees:

1,200

Industry:

Medical - Instruments & Supplies

Sector:

Healthcare

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

7555 Innovation Way
Mason, OH 45040

CIK: 0001323885
ISIN: US04963C2098
CUSIP: 04963C209